Mexiletine in Dogs

Mexiletine is a Class IB antiarrhythmic agent that functions similarly to the local anesthetic lidocaine but is formulated for oral administration. It is most frequently indicated for the long-term management of ventricular tachycardia and other serious ventricular rhythm disturbances. Because it is often used in cases where other primary treatments may prove insufficient, veterinarians frequently combine it with Amiodarone to achieve a synergistic effect, particularly in canine patients diagnosed with arrhythmogenic right ventricular cardiomyopathy (ARVC). By stabilizing the electrical conduction pathways in the heart, this medication helps prevent the dangerous heart rhythm irregularities that can lead to syncope or sudden cardiac death. In complex clinical scenarios, mexiletine is sometimes integrated into a broader cardiac treatment protocol alongside Atenolol, which aids in reducing myocardial oxygen demand and limiting sympathetic drive. These combination therapies require rigorous monitoring via Holter ECG testing to ensure the dosage remains both effective and safe for the specific patient. When managing dogs with concurrent heart failure, clinicians must exercise caution, as the medication is often administered in conjunction with Furosemide to address pulmonary edema or fluid retention. Proper fluid management is critical because the electrolyte shifts caused by diuretics can potentially alter how mexiletine interacts with cardiac tissues. Additionally, if the patient shows signs of reduced cardiac output, vasodilators like Hydralazine might be utilized to support circulation, provided the antiarrhythmic efficacy remains stable under the guidance of a veterinary cardiologist.